Zacks Research Lowers Earnings Estimates for Surmodics

Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Equities research analysts at Zacks Research cut their FY2025 earnings estimates for Surmodics in a note issued to investors on Tuesday, April 29th. Zacks Research analyst D. Dey now anticipates that the company will post earnings per share of ($0.02) for the year, down from their previous forecast of $0.02. The consensus estimate for Surmodics' current full-year earnings is $0.20 per share. Zacks Research also issued estimates for Surmodics' FY2026 earnings at $0.21 EPS.

Several other equities research analysts also recently weighed in on SRDX. StockNews.com started coverage on Surmodics in a report on Monday, February 3rd. They issued a "hold" rating for the company. Needham & Company LLC reissued a "hold" rating on shares of Surmodics in a report on Wednesday, April 30th. Finally, Lake Street Capital raised Surmodics from a "hold" rating to a "buy" rating and set a $43.00 target price for the company in a report on Friday, March 7th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $43.00.

Surmodics Stock Up 0.6 %

Shares of NASDAQ SRDX traded up $0.16 during mid-day trading on Friday, reaching $27.53. 8,437 shares of the company were exchanged, compared to its average volume of 276,319. The company has a quick ratio of 4.29, a current ratio of 5.45 and a debt-to-equity ratio of 0.26. The stock has a market cap of $393.65 million, a price-to-earnings ratio of -27.26 and a beta of 1.32. The firm has a 50-day moving average of $29.13 and a 200 day moving average of $34.73. Surmodics has a 1 year low of $26.00 and a 1 year high of $42.44.

Surmodics (NASDAQ:SRDX - Get Free Report) last announced its earnings results on Wednesday, April 30th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.07). The business had revenue of $28.09 million for the quarter, compared to analysts' expectations of $32.23 million. Surmodics had a negative net margin of 11.48% and a negative return on equity of 4.39%.

Hedge Funds Weigh In On Surmodics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Modus Advisors LLC acquired a new position in shares of Surmodics during the 4th quarter valued at about $40,000. R Squared Ltd purchased a new stake in shares of Surmodics in the 4th quarter valued at approximately $55,000. Legal & General Group Plc increased its holdings in shares of Surmodics by 34.2% during the 4th quarter. Legal & General Group Plc now owns 3,452 shares of the company's stock worth $137,000 after buying an additional 880 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new stake in shares of Surmodics during the 4th quarter valued at approximately $217,000. Finally, Polymer Capital Management US LLC acquired a new position in Surmodics in the fourth quarter valued at approximately $255,000. Institutional investors and hedge funds own 96.63% of the company's stock.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).